AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04033861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Study NCT04033861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
Study NCT00328211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)
Description: 15 mg/kg/day for 18 days
Study NCT00328211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sphingomyelin
Description: 1000mg/day for 19 days
Study NCT00328211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C13 Stable isotope of Cholesterol
Description: Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
Study NCT01965366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality exposure therapy
Description: Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
Study NCT01965366 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual reality exposure therapy
Description: Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
Study NCT01965366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg DEX
Description: A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
Study NCT01208974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple-Sparing Mastectomy
Description: Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
Study NCT01208974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction
Description: Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
Study NCT01208974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Surgery
Description: Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
Study NCT02774057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sulfate
Description: 195 mg Iron supplement
Study NCT01208974 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Nipple-Areolar Complex RT
Description: Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
Study NCT03669926 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Digital Breast Tomosynthesis+synthetic mammography
Description: Two-view tomosynthesis performed with GE Senographe Pristina.
Study NCT02673931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byetta (Lilly, Exenatide)
Description: See description of arms
Study NCT02673931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conoxia (AGA, oxygen)
Description: See description arms
Study NCT02673931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conoxia (AGA, oxygen)
Description: See description arms
Study NCT02673931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20% Human Albumin
Study NCT03722563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laparoscopic hysterectomy with sacrocolpopexy
Description: Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
Study NCT03722563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic hysterectomy with lateral suspension
Description: Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
Study NCT01915134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Endostatin plus gemcitabine and cisplatin
Description: target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
Study NCT01915134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and cisplatin
Description: only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
Study NCT01703364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days
Study NCT00540280 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin
Description: Surgery + Chemo + RT
Study NCT04423068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth II
Description: SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
Study NCT04423068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive
Description: The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet
Study NCT02486328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Dosage adjustment
Study NCT02486328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meperidine
Description: Dosage adjustment
Study NCT02486328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Dosage adjustment
Study NCT02486328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Dosage adjustment
Study NCT01143948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine & Glulisine
Description: Basal Glargine \& bolus Glulisine
Study NCT01143948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: Sliding scale regular insulin
Study NCT01143948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH & regular insulin
Description: Basal NPH \& bolus regular insulin
Study NCT01754831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fluoride varnish
Description: Topical application of fluoride varnish on present teeth
Study NCT03341390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily
Study NCT03341390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily
Study NCT03341390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily
Study NCT03341390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: 200 mg of BMS-986177 administered twice daily
Study NCT03341390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg of Placebo administered twice daily
Study NCT00386360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: oral weekly for one year
Study NCT00386360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg risedronate, once a week for one year
Study NCT02594982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intervention bundle (sedation, pain, mobilization and sleep)
Description: Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night
Study NCT04016389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Study NCT04016389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
Study NCT04016389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
Study NCT04016389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trachelectomy
Description: Surgery to remove the cervix but keep the uterus intact.
Study NCT05651048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
Study NCT05651048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BEMER Group
Description: BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
Study NCT03061253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette and behavioural change support.
Description: The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
Study NCT03061253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine-Free Electronic Cigarette and behavioural change support.
Description: Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
Study NCT04188925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36.
Study NCT04188925 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture
Description: Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
Study NCT05651048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape Group
Description: Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
Study NCT00183859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intraperitoneal Irinotecan given every three weeks
Study NCT03061253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy and behavioural change support.
Description: Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
Study NCT00790374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 1)
Description: 20 mg daily BN83495 for 28 days
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles treatment Ferumoxytol/H2O2
Description: Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl
Description: Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study NCT02401191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEX60/PE10
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT00790374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 2)
Description: 40 mg daily BN83495 for 28 days
Study NCT00790374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 3)
Description: 60 mg daily BN83495 for 28 days
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study NCT06110494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study NCT03509298 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT01735916 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CRT-P Implant
Description: The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.
Study NCT01735916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P Implant
Description: The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.
Study NCT03509298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03509298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT04006327 — intervention group
Intervention type: OTHER
Intervention: No intervention will be provided as this study is a cross-sectional observational study.
Description: This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
Study NCT01735916 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CRT-P OFF
Description: Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
Study NCT04585256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trendelenburg positioning
Description: Women positioned in the trendelenburg position prior to external cephalic version
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 35 mg
Description: Oral 35 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 35 mg
Description: Oral 35 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 55 mg
Description: Oral 55 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 55 mg
Description: Oral 55 mg capsule - active
Study NCT06464809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping (KT)
Study NCT06464809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping (KT)
Study NCT02324933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Study NCT02843074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Given intravenously (IV)
Study NCT02843074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by IV